Blog

  • Recent FDA Decisions Signal Shift, with Troubling Implications for Patients and Medical Innovation

    Drug development has always required a surfeit of intestinal fortitude. It can take hundreds of millions of dollars and a decade or more to bring a new drug to market, and each phase of development—from structuring a clinical trial to securing reimbursement from insurers—carries substantial risk. No entity plays a more central role in the process than U.S. Food and Drug Administration (FDA), which is charged with evaluating the safety and efficacy of new drugs, as well as determining…

  • Bullish on Boston: Why Biotech (and More) is Booming

    I spend a lot of time in Boston these days. So do many of my partners. In fact, half of our partnership serves on boards in Boston, and we have about two dozen Boston companies in our active portfolio. This is not a new phenomenon—NEA has always been among the most active VCs in Boston—but today we’re spending more time here than ever before. Why? Because we’re seeing more opportunity here than ever before. This might sound counterintuitive at a time when many in our…

  • Capital Crunch:  Life Sciences Startups Look to New Sources of Funding

    It’s no secret that the flow of capital into the life sciences industry has slowed to a trickle over the last several years. The number of funds being raised continues to decline, with only a handful of firms raising fresh funds in the past two years (including NEA), leaving venture capitalists with a shortage of dry powder and an ever-dwindling appetite for risk. In 2012, the sector saw a 10 percent drop in total dollars invested and a six percent decrease in the number of deals.…